FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer. Duke ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, et al. Clin Cancer Res 2022 Jun 9. pii: 704846. doi: 10.1158/1078-0432.CCR-22-0873.

Read + Share

Amedeo Smart

Independent Medical Education

Duke ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, et al. FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer. Clin Cancer Res 2022 Jun 9. pii: 704846. doi: 10.1158/1078-0432.CCR-22-0873.
PMID: 35679021